Abbott Laboratories
Abbott Laboratories returns on capital
Annual and trailing 12-month returns on invested capital, equity and assets.
ROIC
% · Annual / TTM
ROCE
% · Annual / TTM
ROIIC
% · Annual / TTM
ROE
% · Annual / TTM
ROA
% · Annual / TTM
ROIC − WACC
Percentage points · Scenario
Quarterly data
| Fiscal period | Ended | ROIC% | ROCE% | ROIIC% | ROE% | ROA% | ROIC − WACCPercentage points |
|---|---|---|---|---|---|---|---|
| FY 2026 Q2 | Jun 30, 2026 | 7.77% | 9.07% | — | 10.62% | 5.62% | -0.1 pp |
| FY 2026 Q1 | Mar 31, 2026 | 8.76% | 9.6% | — | 12.49% | 6.54% | 0.9 pp |
| FY 2025 Q4 | Dec 31, 2025 | 11.12% | 11.72% | — | 13.03% | 7.76% | 3.2 pp |
| FY 2025 Q3 | Sep 30, 2025 | — | 11.95% | — | 30.62% | 17.63% | — |
| FY 2025 Q2 | Jun 30, 2025 | — | 11.58% | — | 31.01% | 17.81% | — |
| FY 2025 Q1 | Mar 31, 2025 | — | 11.24% | — | 30.66% | 17.54% | — |
| FY 2024 Q4 | Dec 31, 2024 | — | 10.78% | — | 30.95% | 17.33% | — |
| FY 2024 Q3 | Sep 30, 2024 | 12.12% | 11.3% | 73.66% | 14.87% | 7.88% | 4.2 pp |
| FY 2024 Q2 | Jun 30, 2024 | 11.81% | 10.96% | 54.51% | 14.47% | 7.59% | 3.9 pp |
| FY 2024 Q1 | Mar 31, 2024 | 11.86% | 10.8% | -12.81% | 14.8% | 7.7% | 4 pp |
| FY 2023 Q4 | Dec 31, 2023 | 12.31% | 10.95% | -50.34% | 15.14% | 7.75% | 4.4 pp |
| FY 2023 Q3 | Sep 30, 2023 | 11.22% | 10.13% | -78.42% | 14.06% | 7.13% | 3.3 pp |
| FY 2023 Q2 | Jun 30, 2023 | 11.08% | 10.14% | -194.92% | 13.96% | 7% | 3.2 pp |
| FY 2023 Q1 | Mar 31, 2023 | 12.83% | 11.54% | — | 15.96% | 7.85% | 4.9 pp |
| FY 2022 Q4 | Dec 31, 2022 | 15.85% | 13.82% | — | 19.05% | 9.27% | 8 pp |
| FY 2022 Q3 | Sep 30, 2022 | 18.49% | 15.68% | — | 22.42% | 10.76% | 10.6 pp |
| FY 2022 Q2 | Jun 30, 2022 | 19.67% | 16.68% | 317.82% | 24.24% | 11.6% | 11.8 pp |
| FY 2022 Q1 | Mar 31, 2022 | 17.67% | 15.17% | 215.5% | 22.32% | 10.53% | 9.8 pp |
| FY 2021 Q4 | Dec 31, 2021 | 16.27% | 13.73% | — | 20.53% | 9.57% | 8.4 pp |
| FY 2021 Q3 | Sep 30, 2021 | 16.6% | 14.17% | — | 21.92% | 10.14% | 8.7 pp |
| FY 2021 Q2 | Jun 30, 2021 | 14.68% | 12.54% | — | 19.71% | 8.98% | 6.8 pp |
| FY 2021 Q1 | Mar 31, 2021 | 13.44% | 11.54% | — | 17.86% | 8.2% | 5.5 pp |
| FY 2020 Q4 | Dec 31, 2020 | 10.66% | 9.11% | — | 14.01% | 6.4% | 2.8 pp |
| FY 2020 Q3 | Sep 30, 2020 | 8.19% | 7.38% | — | 10.66% | 4.92% | 0.3 pp |
| FY 2020 Q2 | Jun 30, 2020 | 7.57% | 6.86% | — | 9.95% | 4.53% | -0.3 pp |
| FY 2020 Q1 | Mar 31, 2020 | 8.59% | 7.95% | — | 11.66% | 5.33% | 0.7 pp |
| FY 2019 Q4 | Dec 31, 2019 | 8.91% | 7.87% | — | 11.9% | 5.46% | 1 pp |
| FY 2019 Q3 | Sep 30, 2019 | 7.97% | 7.37% | — | 10.48% | 4.7% | 0.1 pp |
| FY 2019 Q2 | Jun 30, 2019 | 7.23% | 6.91% | — | 9.26% | 4.23% | -0.7 pp |
| FY 2019 Q1 | Mar 31, 2019 | 6.6% | 6.28% | — | 8.38% | 3.79% | -1.3 pp |
| FY 2018 Q4 | Dec 31, 2018 | 6.17% | 5.82% | — | 7.66% | 3.3% | -1.7 pp |
| FY 2018 Q3 | Sep 30, 2018 | 2.24% | 5.16% | -27.85% | 2.8% | 1.23% | -5.7 pp |
| FY 2018 Q2 | Jun 30, 2018 | 2.17% | 4.83% | -11.27% | 2.95% | 1.33% | -5.7 pp |
| FY 2018 Q1 | Mar 31, 2018 | 1.03% | 4.02% | -39.02% | 1.49% | 0.67% | -6.9 pp |
| FY 2017 Q4 | Dec 31, 2017 | 0.74% | 3.05% | -8.32% | 1.82% | 0.74% | -7.2 pp |
| FY 2017 Q3 | Sep 30, 2017 | 4.3% | 4.15% | -3.62% | 7.94% | 3.76% | -3.6 pp |
| FY 2017 Q2 | Jun 30, 2017 | 3.48% | 4.33% | -6.27% | 4.46% | 2.11% | -4.4 pp |
| FY 2017 Q1 | Mar 31, 2017 | 4.38% | 5.15% | -3.61% | 5.75% | 2.72% | -3.5 pp |
| FY 2016 Q4 | Dec 31, 2016 | 9.7% | 8.16% | — | 6.67% | 2.98% | 1.8 pp |
| FY 2016 Q3 | Sep 30, 2016 | 8.31% | 9.52% | -22.66% | 6.52% | 3.37% | 0.4 pp |
| FY 2016 Q2 | Jun 30, 2016 | 8.98% | 8.68% | — | 10.4% | 5.43% | 1.1 pp |
| FY 2016 Q1 | Mar 31, 2016 | 8.72% | 8.54% | — | 11.45% | 5.92% | 0.8 pp |
| FY 2015 Q4 | Dec 31, 2015 | 9.25% | 9.13% | — | 20.61% | 10.72% | 1.4 pp |
| FY 2015 Q3 | Sep 30, 2015 | 8.58% | 8.9% | — | 20.65% | 10.83% | 0.7 pp |
| FY 2015 Q2 | Jun 30, 2015 | 7.91% | 8.7% | -10.22% | 19.32% | 10.56% | 0 pp |
| FY 2015 Q1 | Mar 31, 2015 | 7.3% | 8.96% | — | 18.49% | 9.91% | -0.6 pp |
| FY 2014 Q4 | Dec 31, 2014 | 6.61% | 8.1% | — | 9.74% | 5.42% | -1.3 pp |
| FY 2014 Q3 | Sep 30, 2014 | 6.64% | 8.37% | — | 8.42% | 4.54% | -1.3 pp |
| FY 2014 Q2 | Jun 30, 2014 | 8.51% | 8.17% | — | 10.41% | 5.68% | 0.6 pp |
| FY 2014 Q1 | Mar 31, 2014 | 8.23% | 7.73% | -127.6% | 10.46% | 5.7% | 0.3 pp |
| FY 2013 Q4 | Dec 31, 2013 | 7.67% | 6.02% | — | 9.86% | 4.68% | -0.2 pp |
| FY 2013 Q3 | Sep 30, 2013 | — | 10.75% | — | 11.99% | 5.66% | — |
| FY 2013 Q2 | Jun 30, 2013 | — | 14.72% | — | 17.16% | 7.67% | — |
| FY 2013 Q1 | Mar 31, 2013 | 22.36% | 18.29% | — | 21.92% | 10.02% | 14.5 pp |
| FY 2012 Q4 | Dec 31, 2012 | 22.11% | 16.37% | 73.41% | 23.31% | 9.35% | 14.2 pp |
| FY 2012 Q3 | Sep 30, 2012 | 19.21% | 17% | — | 25.29% | 10.63% | 11.3 pp |
| FY 2012 Q2 | Jun 30, 2012 | 13.66% | 13.99% | — | 19.22% | 7.89% | 5.8 pp |
| FY 2012 Q1 | Mar 31, 2012 | 13.88% | 13.38% | — | 20.39% | 8.23% | 6 pp |
| FY 2011 Q4 | Dec 31, 2011 | 14.76% | 13.22% | — | 20.19% | 7.9% | 6.9 pp |
| FY 2011 Q3 | Sep 30, 2011 | — | 12.79% | — | 19.72% | 7.78% | — |
| FY 2011 Q2 | Jun 30, 2011 | — | 14.34% | — | 22.14% | 8.91% | — |
| FY 2011 Q1 | Mar 31, 2011 | — | 14.33% | — | — | 7.8% | — |
| FY 2010 Q4 | Dec 31, 2010 | 14.44% | 14.93% | -0.71% | 20.39% | 8.27% | 6.5 pp |
| FY 2010 Q3 | Sep 30, 2010 | — | 15.48% | — | — | 8.81% | — |
| FY 2010 Q2 | Jun 30, 2010 | — | 17.72% | — | — | 10.52% | — |
| FY 2010 Q1 | Mar 31, 2010 | — | — | — | — | — | — |
| FY 2009 Q4 | Dec 31, 2009 | — | — | — | — | — | — |
| FY 2009 Q3 | Sep 30, 2009 | — | — | — | — | — | — |
| FY 2009 Q2 | Jun 30, 2009 | — | — | — | — | — | — |
Sources and calculations
Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.
Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.
Quarterly returns use trailing 12-month earnings and period-end balances averaged with the same fiscal quarter one year earlier. NOPAT uses the reported effective tax rate only when pretax profit is positive and the rate is between 0 and 100%. WACC starts at 7.9%, rounded from the Pharmaceuticals benchmark in NYU Stern · January 2026. It is an editable US sector proxy applied across history, not a company estimate; foreign reporting currencies also need a currency-specific assessment.
Market prices: Yahoo Finance · ABT, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.
- ROIC
- NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
- ROCE
- Operating income / average (assets − current liabilities) × 100, using period end and one year earlier.
- ROIIC
- Year-over-year change in annual/TTM NOPAT / positive year-over-year change in invested capital × 100. Capital reductions and missing inputs yield unavailable values.
- ROE
- Earnings attributable to owners / average equity attributable to owners × 100, using period end and one year earlier.
- ROA
- Net income / average total assets × 100, using period end and one year earlier.
- ROIC − WACC
- ROIC less your WACC assumption, in percentage points. The same scenario rate is applied across history; it is not a reported or historical company WACC.